ARS Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
ARS Pharmaceuticals, Inc. (SPRY) reported Increase (Decrease) in Prepaid Expense and Other Assets of $3.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $2.71M.
- ARS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $524.00K, a 89.07% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$284.00K, a 103.92% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.07M, a 312.10% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$656.00K, a 110.60% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $6.19M, a 331.43% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.44M, a 20.99% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.19M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.24M 10-Q · filed 2026-08-13 | $2.95M derived: sum of 3 quarters · filed 2026-08-13 | $1.89M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $524.00K 10-Q · filed 2026-05-15 | $240.00K derived: sum of 2 quarters · filed 2026-05-15 | -$829.00K derived: sum of 3 quarters · filed 2026-05-15 | -$4.93M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$1.35M derived: sum of 2 quarters · filed 2026-03-09 | -$5.45M derived: sum of 3 quarters · filed 2026-08-13 | -$656.00K 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$5.17M derived: sum of 2 quarters · filed 2026-08-13 | -$372.00K 10-Q · filed 2025-11-10 | $6.88M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $697.00K 10-Q · filed 2026-08-13 | $7.95M derived: sum of 3 quarters · filed 2026-08-13 | $8.45M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $4.80M 10-Q · filed 2026-05-15 | $12.05M derived: sum of 2 quarters · filed 2026-05-15 | $12.55M derived: sum of 3 quarters · filed 2026-05-15 | $11.85M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $7.75M derived: sum of 2 quarters · filed 2026-03-09 | $7.06M derived: sum of 3 quarters · filed 2026-03-09 | $6.19M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $504.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$193.00K derived: sum of 2 quarters · filed 2025-11-10 | -$1.06M 10-Q · filed 2025-11-10 | $856.00K derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | -$697.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.56M 10-Q · filed 2025-08-13 | $352.00K derived: sum of 3 quarters · filed 2025-08-13 | $440.00K derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$867.00K 10-Q · filed 2025-05-14 | $1.05M derived: sum of 2 quarters · filed 2025-05-14 | $1.14M derived: sum of 3 quarters · filed 2025-05-14 | $1.01M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.00M derived: sum of 2 quarters · filed 2025-03-20 | $1.88M derived: sum of 3 quarters · filed 2025-03-20 | $1.44M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$36.00K derived: sum of 2 quarters · filed 2024-11-13 | -$481.00K 10-Q · filed 2024-11-13 | $711.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$569.00K 10-Q · filed 2024-08-06 | $623.00K derived: sum of 3 quarters · filed 2024-08-06 | $485.00K derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | -$445.00K 10-Q · filed 2024-05-09 | $747.00K derived: sum of 2 quarters · filed 2024-05-09 | $609.00K derived: sum of 3 quarters · filed 2024-05-09 | $833.00K derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.05M derived: sum of 2 quarters · filed 2024-03-21 | $1.28M derived: sum of 3 quarters · filed 2024-03-21 | $1.19M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | -$138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $86.00K derived: sum of 2 quarters · filed 2023-11-09 | -$6.00K 10-Q · filed 2023-11-09 | -$4.61M 10-Q · filed 2022-11-02 | -$1.79M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $132.00K 10-Q · filed 2023-08-10 | -$2.29M 10-Q · filed 2022-08-11 | -$1.65M derived: sum of 3 quarters · filed 2023-08-10 | -$292.00K derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$92.00K 10-Q · filed 2023-05-15 | $38.00K 10-Q · filed 2022-05-12 | -$1.87M derived: sum of 2 quarters · filed 2023-05-15 | -$516.00K derived: sum of 3 quarters · filed 2023-05-15 | -$1.32M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$424.00K derived: sum of 2 quarters · filed 2023-03-23 | -$1.23M derived: sum of 3 quarters · filed 2023-03-23 | -$1.17M 10-K · filed 2023-03-23 | $3.36M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $554.00K derived: sum of 2 quarters · filed 2022-11-02 | $608.00K 10-Q · filed 2022-11-02 | $3.83M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | -$803.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$749.00K 10-Q · filed 2022-08-11 | $2.47M derived: sum of 3 quarters · filed 2022-08-11 | $2.52M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $54.00K 10-Q · filed 2022-05-12 | $3.28M derived: sum of 2 quarters · filed 2022-05-12 | $3.33M derived: sum of 3 quarters · filed 2022-05-12 | $3.68M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $3.27M derived: sum of 2 quarters · filed 2022-03-31 | $3.63M derived: sum of 3 quarters · filed 2022-03-31 | $3.54M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $405.00K derived: sum of 2 quarters · filed 2021-11-10 | $313.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $353.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $261.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$92.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |